A female infant presented at the age of 4 weeks with dyschezia and bloody streaking of stools which did not improve on elemental formula for proposed cow's milk protein allergy. At 6 months of age perianal ulceration appeared which evolved into multiple fistulas opening into the perineum. A diagnosis of infantile Crohn's disease was made after colonoscopy and histopathology examination and exclusion of other conditions. An 8 week trial of total parenteral nutrition, in addition to corticosteroids, salazopyrine, metronidazole, and azathioprine failed to arrest deterioration of the perianal fistulas. Treatment with the anti-TNFα antibody infliximab was started at 5 mg/kg/dose at 9 months of age. She was given three doses at 0, 2, and 6 weeks, respectively. This resulted in significant healing of her fistulas and cessation of fistula output. This improvement was sustained at the time of last follow-up 10 months after treatment.
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Figure 1
Mucosal inflammation of the caecum and ileocaecal valve at colonoscopy Histopathology of the mucosal biopsy taken from the terminal ileum and different parts of the colon showed moderate increase in the lamina propria of mononuclear inflammatory cells and neutrophils indicating cryptitis and crypt abscess. No granulomata were seen.
Barium meal and follow through showed mild narrowing with irregular outline at the middle of the jejunum and terminal ileum.
Treatment
The patient was treated with total parenteral nutrition for 8 weeks in addition to corticosteroids, salazopyrine, metronidazole, and azathioprine.
After 2 months of treatment with conventional treatment, perianal disease was getting worse. More fistulas appeared and there was more perineal destruction ( fig 2A) .
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Figure 2
Fiqure 2 (A) Perianal fistulas before treatment with infliximab. (B) Perianal fistulas after treatment with infliximab.
The chimeric anti-TNFα antibody infliximab was started after discussion with the parents. An intravenous infusion at a dose of 5 mg/kg was given at 0, 2, and 6 weeks, respectively. It was well tolerated apart from mild allergic skin rash after the second dose. The rash improved after treatment with antihistamine and hydrocortisone. The third dose of infliximab was tolerated.
Outcome and follow-up
After the induction with infliximab, the stool became formed with no blood or mucus. This was followed by gradual and slow reduction in the output from the fistulas with evidence of healing and improvement in the perianal disease ( fig 2B) .
The patient's general condition improved with less irritability and better weight gain. The improvement in her condition was sustained when she was last reviewed at 20 months of age. She gained 4 kg over a 10 month period. During her follow-up she was admitted twice at the age of 12 and 16 months with sepsis secondary to Escherichia coli and Staphylococcus aureus, respectively, for which she was treated.
Discussion
Crohn's disease in infancy is extremely rare. In one Swedish study of 639 children with IBD, only one child had Crohn's disease before the age of 2 years. In a study from Denmark of 103 children with IBD, only five children including one with Crohn's disease were younger than 2 years. The differential diagnosis of infantile Crohn's disease should include allergic colitis as the main cause of non-infectious colitis in this age group ; however, this patient did not respond to elemental formula, and there were no histological changes to suggest allergy.
All infants with non-infective colitis with a proposed diagnosis of Crohn's disease need to be investigated for immunodeficiency since it can mimic the presentation of Crohn's disease, , and could result in lethal consequences following treatment with immunosuppressive therapy. Immune abnormality was excluded in our case by finding normal immunoglobulin, serum complement, total lymphocytes and lymphocyte subset. Nitroblue tetrazolium test was also performed and excluded the possibility of chronic granulomatous disease in this infant.
In the presence of recurrent mouth ulcers and chronic diarrhoea, especially if the diarrhoea is unresponsive to oral prednisolone and sulfasalazine, with the characteristic ulcers in biopsy, Behçet's syndrome should always be considered. Absence of mouth ulcers in this patient and the presence of perianal disease make this possibility unlikely.
Perianal fistulas in infants with Crohn's disease was reported in four infants by Cohen et al and in two infants by Marx et al. Infants can have severe perianal disease even with mild bowel involvement. Extension of the perianal disease to involve the genitalia, whether direct or metastatic through possible microfistulae, can be complicated by anal stricture, which has been reported by the author in older children with Crohn's disease involving the genitalia.
Management of perianal disease in Crohn's patients has always been difficult. Some improvement can occasionally be achieved by the use of metronidazole and azathioprine; however, this improvement is not usually sustained. The reported outcome of surgical intervention in fistulising disease in children is variable. , , Thus conservative treatment is usually recommended. The new biological therapy anti-TNFα has been very successful when used in fistulising disease in adults with Crohn's disease. But experience with this new therapy in young infants is lacking, and there is concern about the immunomodulatory aspects in a young child whose T cell repertoire is developing. This child has normal immune function 10 months following the last dose of infliximab.
It is also important to consider the infection risk of infliximab in this population, since TNFα is an important component of the immune system's response to a variety of infections. TNFα inhibitors can cause serious infections. These infections have included bacterial sepsis, tuberculosis, invasive fungal and other opportunistic infections. , This infant had two episodes of bacterial sepsis with E coli and S aureus that were treated with appropriate antibiotics.
Failure to recognise early symptoms and signs of infection can result in fatal outcome. , Parents should be educated about the recognition of signs and symptoms of infection during and after treatment with infliximab, and should have access to appropriate medical care. This risk of infection must be interpreted in the context of the potential benefits and of the possible adverse effects of conventional therapies. Repair of the fistulas and improvement of the severe skin damage appears so far to justify its use in the case presented here.
Learning points
Crohn's disease should be considered in infants with bloody stools unresponsive to elemental formula.
Infliximab was effective in this young infant with perianal fistulas.
Infliximab is probably safe in the short term, although long term safety is not known.
There is a potential risk for infections in individuals treated with infliximab that needs to be balanced against the potential benefits.
